B.O'Mahony^1,2; J. Mahlangu³; K.Peerlinck⁴; JDWang⁵; G. Lowe⁶; CWTan⁷; A. Giermasz⁸; H.Tran⁹; TLKhoo¹⁰; E. Cockrell¹¹; D.Pepperell¹²; H. Chambost¹³; MFLFernández¹⁴; R.Kazmi¹⁵; E.Majerus¹⁶; MWSkinner^17,18; R.Klamroth¹⁹; J. Quinn²⁰; H.Yu²⁰; WYWong²⁰; A.Lawal²⁰; TMRobinson²⁰; B.Kim²⁰

¹Irish Hemophilia Society;²Trinity College, Dublin, Irland;³ Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand och NHLS, Johannesburg, Sydafrika;⁴ Institutionen för vaskulär medicin och hemostas- och hemofilicentrum, universitetssjukhus Leuven, Leuven, Belgien;⁵ Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan, Kina;⁶ West Midlands Comprehensive Care Hemophilia Centre, Queen Elizabeth Hospital, Birmingham, Storbritannien;⁷ Department of Hematology, Royal Adelaide Hospital, Adelaide, Australien;⁸ Hemophilia Treatment Center, University of California Davis, Sacramento, USA;⁹ Hemostasis & Trombos Unit, Hemophilia Treatment Centre, The Alfred Hospital, Melbourne;¹⁰ Institutet för hematologi, Royal Prince Alfred Hospital, Camperdown, Australien;¹¹ Pediatric Hematology Oncology, Saint Joseph's Children's Hospital, Tampa, USA;¹² Department of Hematology, Fiona Stanley Hospital, Murdoch, Australien;¹³ AP-HM, avdelningen för pediatrisk hematologisk onkologi, Barnsjukhuset La Timone, Aix Marseille University, INSERM, INRA, C2VN, Marseille, Frankrike;¹⁴ Complejo Hospitalario Universitario A Coruña, A Coruña, Spanien;¹⁵ Department of Hematology, Southampton University Hospital, Southampton, Storbritannien;¹⁶ Institutionen för medicin, Washington University i St. Louis, St. Louis;¹⁷ Institute for Policy Advancement Ltd, Washington, USA;¹⁸ McMaster University, Hamilton, Kanada;¹⁹ Comprehensive Care Hemophilia Treatment Center, Vivantes Klinikumim Friedrichshain, Berlin, Tyskland;²⁰ BioMarin Pharmaceutical Inc., Novato, USA